Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.

Immunosuppressed patients receiving oseltamivir for 2009 novel H1N1 influenza A infection may develop drug resistance, leading to treatment failure. Intravenous zanamivir was administered on a compassionate-use basis to a profoundly immunosuppressed pediatric patient with severe oseltamivir-resistant novel H1N1 pneumonia. The regimen was well tolerated and was associated with a decrease in viral burden.

[1]  M. Eichelberger,et al.  Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Boeckh,et al.  How I treat influenza in patients with hematologic malignancies. , 2010, Blood.

[3]  F. Polack,et al.  Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. , 2010, The New England journal of medicine.

[4]  E. Tuomanen,et al.  Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. , 2010, The New England journal of medicine.

[5]  N. Khardori.  Intravenous Zanamivir for Patients with Pneumonitis due to Pandemic (H1N1) 2009 Influenza Virus , 2010 .

[6]  Guy Boivin,et al.  Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. , 2009, The New England journal of medicine.

[7]  J. Silva-Pereyra,et al.  Pathological changes associated with the 2009 H1N1 virus. , 2009, The New England journal of medicine.

[8]  Libo Dong,et al.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. , 2009, The New England journal of medicine.

[9]  Lyn Finelli,et al.  Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. , 2009, The New England journal of medicine.

[10]  W. Lim,et al.  Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[11]  A. Schuchat.  Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[12]  Gerry Barber,et al.  Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[13]  Tanja Popovic,et al.  Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[14]  Phillip Andrew Reece,et al.  Neuraminidase inhibitor resistance in influenza viruses , 2007, Journal of medical virology.

[15]  F. Hayden,et al.  Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. , 2001, The Journal of infectious diseases.

[16]  F. Hayden,et al.  Safety and Efficacy of Intravenous Zanamivir in Preventing Experimental Human Influenza A Virus Infection , 1999, Antimicrobial Agents and Chemotherapy.

[17]  Alan Bye,et al.  Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers , 1999, Clinical pharmacokinetics.